Table 2. The trends of BRAF mutations prevalence of classical PTCs from individual institutions.
| Country | City (State) | Institution (Reference) |
Prevalence of BRAF mutations in classical PTCs | |||||
|---|---|---|---|---|---|---|---|---|
| Period 1 | Period 2 | Period 3 | Period 4 | P | ||||
| US | San Francisco (CA) | UCSF [13] | 1991-1995 38/74 (51.4%) DS |
1996-2000 44/103 (42.7%) DS |
2001-2005 45/51 (88.2%) DS |
<0.001 | ||
| US | Pittsburgh (PA) | Univ. of Pittsburgh [14] | 1974-1985 31/62 (50.0%) FMCA |
1990-1992 16/22 (72.7%) FMCA |
2000 17/24 (70.8%) FMCA |
2009 50/65 (77.0%) FMCA |
0.008 a | |
| Italy | Pisa/ Perugia/ Milan | Endocrine units of Pisa, Milan and Perugia [11] | 1996-2000 21/56 (37.5%) DS |
2001-2005 61/98 (62.2%) DS |
2006-2010 56/106 (52.9%) DS |
0.012 | ||
| Korea | Seoul | Seoul St. Mary's Hospital [18, 19] | 2008-2009 283/355 (79.7%) DS |
2011-2012 165/200 (82.5%) DS |
NS | |||
| Ireland | Dublin | St. James's Hospital [20] | 1982-1992 0/3 (0%) DS |
1993-2002 11/15 (73.3%) DS |
0.043 | |||
| Poland | Kielce | Holycross Cancer Center [21] | 2000-2004 88/152 (57.9%) Three methods b |
2005 – 2009 140/195 (71.8%) Three methods b |
2010 – 2013 189/254 (74.4%) Three methods b |
0.001 a | ||
Abbreviations: NS, not significant; DS, direct sequencing; FMCA, fluorescent melting curve analysis
a P value for trend adjusted for age and sex
b All analyses that were performed prior to 2013 by DS and allele-specific PCR (AS-PCR) were verified by quantitative Real time PCR (qPCR). In total, the authors used qPCR to analyze BRAF mutations in 705/723 PTCs (97.5%). The majority of samples were tested using the three methods (DS, AS-PCR and qPCR).